Skip to main
  1. Stocks
  2. Actuate Therapeutics Inc
  3. Forecast
ACTU

ACTU Stock Forecast & Price Target

ACTU Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Actuate Therapeutics is attractive because elraglusib is showing broad synergy with orally dosed RAS inhibitors, including activity in 20 of 20 PDAC models and 4 of 4 daraxonrasib models, which supports a differentiated combination strategy against refractory tumors. The company also has a clear oral development path with FDA clearance for the Phase 1/2 study, expected 2H26 clinic entry, and the possibility of reaching the 210 ng/mL exposure threshold with one to two 250 mg tablets per day, while cash is modeled to last into 4Q27. Beyond pancreatic cancer, the pediatric program adds optionality: 53% response or disease control in 19 heavily pretreated patients, potential BEACON2 enrollment in 1H27, and possible PRV value of approximately $150M to $200M.

Bears say

Actuate Therapeutics is a clinical-stage biopharmaceutical company with no revenues in 2Q26 and 3Q26, underscoring a business still fully dependent on capital markets rather than product sales. Its losses remain persistent, at $0.20 per diluted share in 2Q26 and $0.14 in 3Q26, while full-year 2026 is projected to show another net loss of $0.57 per diluted share. Liquidity is also a concern, with cash of $4.44M at the end of 2Q26 and $2.10M at 3Q26, even after raising $11.8M, and management said additional capital will be needed beyond October 2027.

ACTU has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Actuate Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

ACTU Analyst Forecast & Price Prediction

Get the latest ACTU stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ACTU

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Actuate Therapeutics Inc (ACTU) Forecast

Analysts have given ACTU a Strong Buy based on their latest research and market trends.

According to 2 analysts, ACTU has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Actuate Therapeutics Inc (ACTU)


ACTU Analyst Forecast & Price Prediction

Get the latest ACTU stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ACTU

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ACTU stock data and trends